Montelukast Efg Teva (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Efg Teva, is a leukotriene receptor antagonist presented as an oral tablet for oral administration. It works by blocking cysteinyl leukotriene receptors, helping to control airway inflammation and nasal symptoms. The medication is prescribed for asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in both adult and pediatric patients under medical supervision.

GNH USA supplies Montelukast Efg Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to manage chronic respiratory and allergic conditions.

Asthma: improves symptom control and reduces the frequency of exacerbations. Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea. Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness - Sore throat

Serious or Rare Side Effects: - Allergic reactions such as angioedema or rash - Mood changes including depression or suicidal thoughts - Hepatic enzyme elevation or liver injury - Neutropenia or other blood dyscrasias - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy, consider the following precautions.

Monitor liver function: obtain baseline and periodic hepatic enzyme tests. Assess psychiatric status: watch for mood alterations or depressive symptoms. Use with caution in severe hepatic impairment: dose adjustment may be required. Avoid in patients with known hypersensitivity to montelukast or any tablet excipients. Pregnancy: discuss potential risks with the prescriber, as safety data are limited. Store at room temperature: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines; review the following.

Major Interactions (Avoid): - Rifampin: strong enzyme inducer that can markedly reduce montelukast exposure. - Ketoconazole: potent CYP3A4 inhibitor that may increase plasma concentrations.

Moderate Interactions (Monitor Closely): - Phenobarbital, carbamazepine, phenytoin: enzyme inducers that may lower effectiveness. - Fluconazole: moderate CYP3A4 inhibitor, may raise drug levels. - Warfarin: potential for altered anticoagulant effect; monitor INR closely.